Elekta AB (SE:EKTA.B)
:EKTA.B
Want to see SE:EKTA.B full AI Analyst Report?
Top Page
Elekta AB
(EKTA.B)
Select Model
Select Model
Rating:54Neutral
Price Target:
kr54.00
▼(-5.18% Downside)
Action:ReiteratedDate:03/07/26
The score is held back primarily by deteriorating profitability (TTM net loss and margin compression) and increased leverage, with valuation also pressured by an extremely high P/E. These negatives are partly balanced by strong free cash flow generation and supportive technicals with the share price trending above key moving averages.
Positive Factors
Strong free cash flow
Consistent operating and free cash flow (~SEK 2.0B TTM) provides a durable liquidity cushion independent of reported earnings. Strong cash conversion supports capex for product upgrades, funding service operations, and deleveraging or strategic investment even if reported profits remain pressured.
Negative Factors
Revenue decline and net loss
Falling revenue and a move to a small net loss signal weakening demand or adverse mix, which can undermine scale economics and investment capacity. Sustained top-line decline pressures margins, reduces ability to fund R&D, and increases reliance on cash reserves or external financing.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong free cash flow
Consistent operating and free cash flow (~SEK 2.0B TTM) provides a durable liquidity cushion independent of reported earnings. Strong cash conversion supports capex for product upgrades, funding service operations, and deleveraging or strategic investment even if reported profits remain pressured.
Read all positive factors
Elekta AB (EKTA.B) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr20.38B
Dividend Yield4.25%
Average Volume (3M)1.33M
Price to Earnings (P/E)546.4
Beta (1Y)1.05
Revenue Growth-4.32%
EPS Growth-103.84%
CountrySE
Employees4,541
SectorGeneral
Sector StrengthN/A
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)0.88
Shares Outstanding368,587,650
10 Day Avg. Volume896,136
30 Day Avg. Volume1,329,676
Financial Highlights & Ratios
PEG Ratio-0.97
Price to Book (P/B)2.13
Price to Sales (P/S)1.04
P/FCF Ratio17.73
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
kr52.50Price Target Upside-7.81% Downside
Rating ConsensusModerate Sell
Number of Analyst Covering2
EPS Forecast (FY)3.99
Revenue Forecast (FY)kr17.56B
Elekta AB Business Overview & Revenue Model
Company Description
Elekta AB (publ), a medical technology company, provides clinical solutions for treating cancer and brain disorders worldwide. The company offers Versa HD, a brain metastases solution; Elekta Unity, a MR-Linac technology; Elekta Harmony, a linear ...
How the Company Makes Money
Elekta makes money mainly by selling and supporting radiation therapy and related software solutions to healthcare providers. Key revenue streams typically include: (1) Hardware/system sales: revenue from delivering radiation therapy systems and o...
Elekta AB Financial Statement Overview
Summary
Income Statement
44
Neutral
Balance Sheet
52
Neutral
Cash Flow
63
Positive
| Breakdown | TTM | Apr 2025 | Apr 2024 | Apr 2023 | Apr 2022 | Apr 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 17.11B | 18.02B | 18.12B | 16.87B | 14.55B | 13.76B |
| Gross Profit | 6.42B | 6.75B | 6.80B | 6.35B | 5.44B | 5.61B |
| EBITDA | 1.80B | 2.19B | 3.29B | 2.57B | 2.69B | 3.07B |
| Net Income | -39.00M | 237.00M | 1.30B | 943.00M | 1.15B | 1.25B |
Balance Sheet | ||||||
| Total Assets | 27.68B | 28.98B | 31.41B | 29.61B | 26.30B | 24.84B |
| Cash, Cash Equivalents and Short-Term Investments | 2.54B | 2.96B | 2.78B | 3.27B | 3.07B | 4.40B |
| Total Debt | 7.28B | 7.57B | 7.25B | 6.67B | 5.70B | 6.24B |
| Total Liabilities | 19.67B | 20.13B | 20.63B | 19.88B | 17.39B | 16.65B |
| Stockholders Equity | 7.97B | 8.80B | 10.78B | 9.73B | 8.91B | 8.20B |
Cash Flow | ||||||
| Free Cash Flow | 2.00B | 1.06B | 817.00M | 400.00M | 450.00M | 1.71B |
| Operating Cash Flow | 2.65B | 2.63B | 2.46B | 1.96B | 1.86B | 2.55B |
| Investing Cash Flow | -1.15B | -1.67B | -1.92B | -1.61B | -1.65B | -613.00M |
| Financing Cash Flow | -2.29B | -607.00M | -1.10B | -129.00M | -1.73B | -3.60B |
Elekta AB Technical Analysis
Positive
56.95
Price Trends
55.73
Positive
55.43
Positive
50.88
Positive
Market Momentum
0.16
Negative
58.12
Neutral
91.64
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:EKTA.B, the sentiment is Positive. The current price of 56.95 is above the 20-day moving average (MA) of 55.63, above the 50-day MA of 55.73, and above the 200-day MA of 50.88, indicating a bullish trend. The MACD of 0.16 indicates Negative momentum. The RSI at 58.12 is Neutral, neither overbought nor oversold. The STOCH value of 91.64 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:EKTA.B.
Elekta AB Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | kr31.73B | 49.61 | 20.86% | ― | 21.30% | 68.92% | |
64 Neutral | kr6.23B | 34.29 | 24.30% | 1.32% | 12.77% | 11.92% | |
64 Neutral | kr7.21B | 31.86 | 15.16% | ― | 16.68% | 4.83% | |
58 Neutral | kr14.13B | 31.59 | 3.34% | 0.80% | -5.68% | -1106.19% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
55 Neutral | kr847.55M | 103.06 | 6.93% | ― | -5.76% | -81.59% | |
54 Neutral | kr20.38B | 546.38 | 3.08% | 4.25% | -4.32% | -103.84% |
* General Sector Average
SE:EKTA.B
Elekta AB
53.35
6.65
14.24%
SE:VITR
Vitrolife AB
104.30
-53.30
-33.82%
SE:CAMX
Camurus AB
529.00
-92.00
-14.81%
SE:RAY.B
RaySearch Laboratories AB
181.80
-76.13
-29.51%
SE:CRAD.B
C-Rad AB Class B
25.10
-4.90
-16.33%
SE:MCAP
MedCap AB
478.00
43.00
9.89%
Elekta AB Corporate Events
Elekta Sets June Capital Markets Day to Outline Strategy and Financial Targets
Apr 17, 2026
Elekta will host a Capital Markets Day on June 17, 2026, in Stockholm, inviting investors, analysts and other stakeholders to attend in person or online. The company plans to outline its strategy and financial targets, with CEO Jakob Just-Bomholt,...
Elekta absorbs heavy restructuring charge as margin initiatives start to bite
Mar 5, 2026
Elekta reported a mixed third quarter, with net sales up 2 percent in constant currencies but down 10 percent in SEK, as currency headwinds and tariffs weighed on reported results. The company maintained a strong book-to-bill ratio of 1.17, driven...
Elekta Adjusts Nomination Committee Ahead of 2026 Annual General Meeting
Feb 25, 2026
Elekta has announced a change in its Nomination Committee ahead of the Annual General Meeting scheduled for September 3, 2026, with Anna Magnusson replacing Thomas Wuolikainen as the Fourth Swedish National Pension Fund’s representative. Fol...
Elekta Schedules March 5 Call to Present Q3 2025/26 Results
Feb 19, 2026
Elekta has invited analysts and investors to a conference call and webcast on March 5 at 9:00 a.m. CET to present its third-quarter 2025/26 financial results, with the interim report scheduled for release earlier that morning. The session, led by ...
Elekta Unveils Cost-Cutting Overhaul and Growth Push in U.S. and China
Jan 30, 2026
Elekta has outlined a new strategic direction centered on growth, innovation and operational efficiency, anchored in a revamped operating model. As part of this transformation, the company will cut 450 jobs, targeting annual cost savings of more t...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.